Rationale for Hypertonic Saline Therapy for Cystic Fibrosis Lung Disease

Robert Tarran; Scott Donaldson; Richard C. Boucher

doi:10.1055/s-2007-981650

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2007; 28(3): 295-302
DOI: 10.1055/s-2007-981650

Rationale for Hypertonic Saline Therapy for Cystic Fibrosis Lung Disease

Robert Tarran¹ , Scott Donaldson¹ , Richard C. Boucher¹

¹Cystic Fibrosis/Pulmonary Research and Treatment Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Abstract

ABSTRACT

Cystic fibrosis (CF) is caused by alterations in the CF transmembrane conductance regulator (CFTCR) gene. More than 1400 mutations in the CFTCR gene have been described, but the most common mutation (noted in 70% of CF chromosomes) is ΔF508. Alterations in the CFTCR gene result in deranged sodium and chloride ion transport channels. This leads to failure of airway epithelia to hydrate their surfaces normally, particularly in response to infectious or toxic insults. Additional effects include mucus adhesion to airway surface, chronic inflammation, and infections. The concept that airway surface dehydration can cause CF-like lung disease is supported by in vitro data and in vivo animal models. Rehydrating airway surfaces may reduce or prevent lung injury and damage. Short- and longer term studies have shown that inhalation of hypertonic saline is well tolerated and improves lung function, reduces exacerbations, and improves quality of life in CF patients. This review discusses the importance of airway epithelial sodium and chloride channels in the pathogenesis of CF, and strategies (particularly the use of inhaled hypertonic saline) to reverse or minimize lung inflammation and injury in this disease.

KEYWORDS

Cystic fibrosis - cystic fibrosis transmembrane conductance regulator (CFTCR) gene - hypertonic saline - sodium and calcium channel - osmotic gradient

Full Text

References

REFERENCES

1 Davis P B. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006; 173 475-482
2 Kerem B, Rommens J M, Buchanan J A et al.. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989; 245 1073-1080
3 Riordan J R, Rommens J M, Kerem B-T et al.. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245 1066-1073
4 Guggino W B, Stanton B A. New insights into cystic fibrosis: molecular switches that regulate CFTCR. Nat Rev Mol Cell Biol. 2006; 7 426-436
5 Anderson M P, Rich D P, Gregory R J, Smith A E, Welsh M J. Generation of cAMP-activated chloride currents by expression of CFTCR. Science. 1991; 251 679-682
6 Jia Y, Mathews C J, Hanrahan J W. Phosphorylation by protein kinase C is required for acute activation of cystic fibrosis transmembrane conductance regulator by protein kinase A. J Biol Chem. 1997; 272 4978-4984
7 Boucher R C, Stutts M J, Knowles M R, Cantley L, Gatzy J T. Na⁺ transport in cystic fibrosis respiratory epithelia: abnormal basal rate and response to adenylate cyclase activation. J Clin Invest. 1986; 78 1245-1252
8 Stutts M J, Canessa C M, Olsen J C et al.. CFTCR as a cAMP-dependent regulator of sodium channels. Science. 1995; 269 847-850
9 Cheng S H, Gregory R J, Marshall J et al.. Defective intracellular transport and processing of CFTCR is the molecular basis of most cystic fibrosis. Cell. 1990; 63 827-834
10 Riordan J R. Assembly of functional CFTCR chloride channels. Annu Rev Physiol. 2005; 67 701-718
11 Matsui H, Grubb B R, Tarran R et al.. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998; 95 1005-1015
12 Matsui H, Randell S H, Peretti S W, Davis C W, Boucher R C. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest. 1998; 102 1125-1131
13 Matsui H, Davis C W, Tarran R, Boucher R C. Osmotic water permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia. J Clin Invest. 2000; 105 1419-1427
14 Tarran R, Trout L, Donaldson S H, Boucher R C. Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J Gen Physiol. 2006; 127 591-604
15 Mall M, Wissner A, Gonska T et al.. Inhibition of amiloride-sensitive epithelial Na( + ) absorption by extracellular nucleotides in human normal and cystic fibrosis airways. Am J Respir Cell Mol Biol. 2000; 23 755-761
16 Tarran R, Button B, Picher M et al.. Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections. J Biol Chem. 2005; 280 35751-35759
17 Tarran R, Button B, Boucher R C. Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress. Annu Rev Physiol. 2006; 68 543-561
18 van Ewijk B E, van der Zalm M M, Wolfs T F, van der Ent C K. Viral respiratory infections in cystic fibrosis. J Cyst Fibros. 2005; 4(Suppl 2) 31-36
19 Abman S H, Ogle J W, Butler-Simon N, Rumack C M, Accurso F J. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988; 113 826-830
20 Mall M, Grubb B R, Harkema J R, O'Neal W K, Boucher R C. Increased airway epithelial Na⁺ absorption produces cystic fibrosis-like lung disease in mice. Nat Med. 2004; 10 487-493
21 Matthews L W, Spector S, Lemm J, Potter J L. Studies on pulmonary secretions, I: The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis. 1963; 88 199-204
22 Potter J L, Matthews L W, Spector S, Lemm J. Studies of pulmonary secretions, II: Osmolarity and the ionic environment of pulmonary secretions from patients with cystic fibrosis, bronchiectasis and laryngectomy. Am Rev Respir Dis. 1967; 96 83-87
23 Zuelzer W W, Newton Jr W A. The pathogenesis of fibrocystic disease of the pancreas: a study of 36 cases with special reference to the pulmonary lesions. Pediatrics. 1949; 4 53-69
24 Eng P A, Morton J, Douglass J A, Riedler J, Wilson J, Robertson C F. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol. 1996; 21 77-83
25 Robinson M, Regnis J A, Bailey D L, King M, Bautovich G J, Bye P T. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med. 1996; 153 1503-1509
26 Donaldson S H, Bennett W D, Zeman K L, Knowles M R, Tarran R, Boucher R C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006; 354 241-250
27 Elkins M R, Robinson M, Rose B R et al.. A controlled trial of long-term Inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006; 354 229-240
28 Willumsen N J, Boucher R C. Sodium transport and intracellular sodium activity in cultured human nasal epithelium. Am J Physiol. 1991; 261(2 Pt 1) C319-C331
29 Willumsen N J, Boucher R C. Transcellular sodium transport in cultured cystic fibrosis human nasal epithelium. Am J Physiol. 1991; 261(2 Pt 1) C332-C341
30 Willumsen N J, Davis C W, Boucher R C. Cellular Cl^- transport in cultured cystic fibrosis airway epithelium. Am J Physiol. 1989; 256(5 Pt 1) C1045-C1053
31 Willumsen N J, Davis C W, Boucher R C. Intracellular Cl^- activity and cellular Cl^- pathways in cultured human airway epithelium. Am J Physiol. 1989; 256(5 Pt 1) C1033-C1044
32 Willumsen N J, Boucher R C. Shunt resistance and ion permeabilities in normal and cystic fibrosis airway epithelium. Am J Physiol. 1989; 256(5 Pt 1) C1054-C1063
33 Knowles M R, Stutts M J, Spock A, Fischer N, Gatzy J T, Boucher R C. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science. 1983; 221 1067-1070
34 Knowles M, Murray G, Shallal J et al.. Bioelectric properties and ion flow across excised human bronchi. J Appl Physiol. 1984; 56 868-877
35 Willumsen N J, Boucher R C. Activation of an apical Cl^- conductance by Ca^{2 +} ionophores in cystic fibrosis airway epithelia. Am J Physiol. 1989; 256(2 Pt 1) C226-C233
36 Levin M H, Sullivan S, Nielson D, Yang B, Finkbeiner W E, Verkman A S. Hypertonic saline therapy in cystic fibrosis: evidence against the proposed mechanism involving aquaporins. J Biol Chem. 2006; 281 25803-25812
37 Tarran R, Grubb B R, Parsons D et al.. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell. 2001; 8 149-158
38 Sood N, Bennett W D, Zeman K et al.. Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am J Respir Crit Care Med. 2002; 167 158-163
39 Knowles M R, Robinson J M, Wood R E et al.. Ion composition of airway surface liquid of patients with cystic fibrosis as compared to normal and disease-control subjects. J Clin Invest. 1997; 100 2588-2595
40 Kotaru C, Hejal R B, Finigan J H et al.. Desiccation and hypertonicity of the airway surface fluid and thermally induced asthma. J Appl Physiol. 2003; 94 227-233

Richard C BoucherM.D.

Cystic Fibrosis/Pulmonary Research and Treatment Center, CB#7248 7011 Thurston-Bowles Bldg.

The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7248

Email: rboucher@med.unc.edu